Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age

Sanofi

Status and phase

Completed

Phase 2

Conditions

Meningococcal Infection

Meningitis

Treatments

Biological: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)

Biological: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00643916

MTA26

Details and patient eligibility

About

The purpose of this clinical trial is to describe the safety and immunogenicity of one or two doses of Menactra® (TetraMenD) administered in children less than 2 years of age.

Primary Objective:

To describe the immunogenicity profile of one or two doses of Menactra® (TetraMenD) when administered to subjects aged 9, 12, 15, or 18 months in comparison to the immunogenicity of one dose of Menomune® when administered to children aged 3 years to <6 years of age.

Full description

This is a Phase II, open-label, parallel, exploratory, multi-center study in healthy toddlers.

Enrollment

378 patients

Sex

All

Ages

9 months to 5 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria :

Aged either 9, 12, 15 or 18 months of age or 3 to < 6 years of age on the day of inclusion.
Informed consent form that has been approved by the site's Institutional Review Board (IRB) and signed by the parent or legal guardian
Able to attend all scheduled visits and to comply with all trial procedures

Exclusion Criteria :

History of a serious chronic disease that could interfere with trial conduct or completion.
Known or suspected impairment of immunologic function.
Acute medical illness with or without fever within the last 72 hours, or rectal temperature ≥ 100.4°F (≥ 38.0°C) or axillary temperature ≥ 99.4°F (≥ 37.4°C) on the day of inclusion.
History of invasive meningococcal disease (confirmed either clinically, serologically or microbiologically) or previous meningococcal vaccination.
Administration of immune globulin or other blood products within 3 months, or oral or parenteral corticosteroids or other immunosuppressive therapy within the last 6 weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
Antibiotic therapy within the 72 hours prior to having any blood sample drawn.
Received or scheduled to receive any vaccine in the 28-day period prior to receipt of either dose of the study vaccine, or scheduled to receive any vaccination other than influenza vaccination and hyposensitization therapy in the 28-day period after receipt of either dose of the study vaccine. Hyposensitization therapy and influenza vaccination may be received up to two weeks before or after receiving the trial vaccine.
Suspected or known hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances.
Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination
Unable to attend one or more of the scheduled visits or to comply with the study procedures.
Participation in another clinical trial in the 4 weeks preceding enrollment.
Planned participation in another clinical trial during the present trial period.
Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.

Trial design

Primary purpose

Prevention

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

378 participants in 6 patient groups

Vaccinated at Age 9 and 12 Months

Experimental group

Description:

Participants received Menactra® vaccine at 9 and 12 Months of age

Treatment:

Biological: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)

Vaccinated at Age 9 and 15 Months

Experimental group

Description:

Participants received Menactra® vaccine at 9 and 15 Months of age

Treatment:

Biological: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)

Vaccinated at Age 12 and 15 Months

Experimental group

Description:

Participants received Menactra® vaccine at Age 12 and 12 Months of age

Treatment:

Biological: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)

Vaccinated at Age 15 Months

Experimental group

Description:

Participants received Menactra® vaccine at 15 Months of age

Treatment:

Biological: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)

Vaccinated at Age 18 Months

Experimental group

Description:

Participants received Menactra® vaccine at 18 Months of age

Treatment:

Biological: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)

Vaccinated at Age 3 Years to <6 Years

Active Comparator group

Description:

Participants received Menomune® vaccine at Age 3 years to \<6 years of age

Treatment:

Biological: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)

Trial contacts and locations

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms